BARRETT’S ESOPHAGUS AND ASSOCIATED ADENOCARCINOMA - Studies on pathogenesis, clinical staging, and cost-utility of cancer treatment
نویسندگان
چکیده
.................................................................................................................... 8 INTRODUCTION ......................................................................................................... 10 REVIEW OF THE LITERATURE ................................................................................. 12 1. Barrett’s esophagus .................................................................................................... 12 1.1. Defi nition .......................................................................................................... 12 1.2. Pathogenesis ..................................................................................................... 12 1.3. Diagnosis ........................................................................................................... 16 1.4. Epidemiology .................................................................................................... 17 1.5. Treatment of gastroesophageal refl ux disease on Barrett’s esophagus patients 18 1.6. Dysplasia in Barrett’s esophagus ...................................................................... 18 2. Adenocarcinoma associated with Barrett’s esophagus ............................................ 21 2.1. Epidemiology .................................................................................................... 21 2.2. Classifi cation of esophageal and gastroesophageal junction adenocarcinomas .............................................................................................. 21 2.3. Diagnosis ........................................................................................................... 23 2.4. Treatment of esophageal and gastroesophageal junctional adenocarcinomas 26 2.5. Oxidative stress in development of Barrett’s esophagus and adenocarcinoma ............................................................................................... 30 2.6. Cost-effectiveness, cost-utility, and cost-benefi t of treatment of esophageal and esophagogastric junction carcinomas ................................... 31 AIMS OF THE STUDY .................................................................................................. 34 PATIENTS AND METHODS ........................................................................................ 35 1. Patients ...................................................................................................................... 35 2. Methods ..................................................................................................................... 35 2.1. Tissue sample collection .................................................................................. 35 2.2. Analysis of superoxide dismutase (SOD) and myeloperoxidase (MP) activities and glutathione content .................................................................... 36 2.3. Analysis of 8-hydroxydeoxyguanosine (8-OHdG) .......................................... 36 2.4. Positron emission tomography (PET) imaging ............................................... 37 2.5. Health-related quality of life (HRQoL) ........................................................... 37 2.6. Cost-utility ........................................................................................................ 38 2.7. Statistical methods ............................................................................................ 38
منابع مشابه
MicroRNAs in Barrett's esophagus: future prospects
Esophageal adenocarcinoma is an aggressive malignancy with a poor prognosis. In Western countries, the incidence of esophageal adenocarcinoma has increased dramatically in the last three decades. To improve patient survival and reduce disease burden, early-stage detection, or better yet, preventing the progression of esophageal adenocarcinoma from its premalignant lesions, constitute the best s...
متن کاملEDITORIALS Cyclooxygenase-2 Inhibitor Therapy for the Prevention of Esophageal Adenocarcinoma in Barrett’s Esophagus
The outcome for patients diagnosed with esophageal adenocarcinoma remains abysmal despite a better understanding of the molecular events that underlie development of the disease. Additionally, the incidence for this type of esophageal carcinoma has been rapidly increasing in the United States over the last three decades (1). Esophageal adenocarcinoma often occurs in the setting of Barrett’s eso...
متن کاملCyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus.
The outcome for patients diagnosed with esophageal adenocarcinoma remains abysmal despite a better understanding of the molecular events that underlie development of the disease. Additionally, the incidence for this type of esophageal carcinoma has been rapidly increasing in the United States over the last three decades (1). Esophageal adenocarcinoma often occurs in the setting of Barrett’s eso...
متن کاملBarrett’s Esophagus - American Family Physician
managed in the primary care setting. Surveys suggest that approximately 20 percent of U.S. adults have symptoms of GERD at least once a week.4 A subgroup of patients with GERD develop severe complications that include erosive esophagitis, stricture formation, Barrett’s esophagus, and adenocarcinoma of the esophagus. Because Barrett’s esophagus is thought to be associated with the development of...
متن کاملPii: S1091-255x(02)00003-3
The glutathione S–transferases (GSTs) are a family of enzymes that play an important role in the prevention of cancer by detoxifying numerous potentially carcinogenic compounds. GSTs conjugate reduced glutathione to a variety of electrophilic and hydrophobic compounds, converting them into more soluble, more easily excretable compounds. Decreased glutathione S–transferase-pi (GSTPI) enzyme acti...
متن کامل